Atterocor Inc.
Treating adrenal cancer with an ACAT1 inhibitor
This article was originally published in Start Up
Executive Summary
Atterocor Inc. aims to destroy, or at least interfere with, pathological processes in cortical cells of the adrenal glands. The start-up has secured orphan designation and initiated Phase I trials on a compound it calls ATR-101, a novel ACAT1 inhibitor that induces apoptosis, in people with adrenocortical carcinoma, or adrenal cancer, a truly rare and fatal disease.